Who are Metoclopramide hydrochloride monohydrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ziprasidone Injection, Haloperidol + Ketamine, Latuda (Lurasidone), Quetiapine 600mg, ziprasidone or olanzapine, Placebo domperidone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metoclopramide-hydrochloride-monohydrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Metoclopramide hydrochloride monohydrate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metoclopramide hydrochloride monohydrate (Metoclopramide hydrochloride monohydrate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine antagonist / Antiemetic / Prokinetic agent. Area: Gastroenterology.

marketed Dopamine antagonist / Antiemetic / Prokinetic agent Dopamine D2 receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Metoclopramide hydrochloride monohydrate (Metoclopramide hydrochloride monohydrate) — CM Chungmu Hospital. Metoclopramide blocks dopamine receptors in the chemoreceptor trigger zone and enhances acetylcholine effects on gastric muscle to increase gastric contractions and accelerate gastric emptying.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Metoclopramide hydrochloride monohydrate TARGET	Metoclopramide hydrochloride monohydrate	CM Chungmu Hospital	marketed	Dopamine antagonist / Antiemetic / Prokinetic agent	Dopamine D2 receptor
Ziprasidone Injection	Ziprasidone Injection	Hennepin Healthcare Research Institute	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Haloperidol + Ketamine	Haloperidol + Ketamine	University Hospital, Basel, Switzerland	marketed	Antipsychotic + Dissociative anesthetic combination	Dopamine D2 receptor (haloperidol); NMDA glutamate receptor (ketamine)
Latuda (Lurasidone)	Latuda (Lurasidone)	Massachusetts General Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
Quetiapine 600mg	Quetiapine 600mg	AstraZeneca	marketed	atypical antipsychotic	["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
ziprasidone or olanzapine	ziprasidone or olanzapine	Medical University of Vienna	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Placebo domperidone	Placebo domperidone	Seoul National University Hospital	marketed	Dopamine antagonist / Prokinetic agent	Dopamine D2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine antagonist / Antiemetic / Prokinetic agent class)

CM Chungmu Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metoclopramide hydrochloride monohydrate — Competitive Intelligence Brief. https://druglandscape.com/ci/metoclopramide-hydrochloride-monohydrate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab